FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Diltiazem Hydrochloride
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 02/07/2020)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10) Backorder. Estimated recovery March 2020. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25) Backorder. Estimated recovery March 2020. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26) Backorder. Estimated recovery March 2020 Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05) Backorder. Estimated recovery March 2020. Demand increase for the drug

Athenex Pharmaceutical Division, LLC (Athenex) (Reverified 05/11/2020)

Company Contact Information:
855-273-0154

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg/5mL vial (NDC 70860-301-05) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
50 mg/10mL vial (NDC 70860-301-10) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
125 mg/25mL vial (NDC 70860-301-25) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 05/12/2020)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10) Inventory is currently available. Additional lots will be scheduled for manufacturing Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10) Product is currently on allocation. Additional lots will be scheduled for manufacturing in the February - March 2020 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10) This presentation is temporarily on backorder Additional lots are scheduled for manufacturing in the May 2020 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Reverified 07/01/2020)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03) Available Other
25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01) Next Delivery and Estimated Recovery: August 2020 Shortage per Manufacturer: Manufacturing Delay Other
50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English